JDRF Drives Next-Generation Type 1 Diabetes Research With New Partnerships & Breakthrough Science

NEW YORK, Dec. 20, 2018 /PRNewswire/ — JDRF, the leading global organization funding type 1 diabetes (T1D) research, announced today that it made progressive advances this year on its path to a cure, funding new therapeutic developments to better treat the chronic autoimmune disease affecting 1.25 million Americans.

“No organization in the world is more committed to type 1 diabetes research than JDRF,” said Derek Rapp, CEO and president of JDRF. “To date, our organization has committed more than $2.25 billion to T1D research, a significant majority of which is being directed toward curing the disease. The heavy weighting toward cure research continued in 2018, as it will going forward. Additionally, our efforts in advocacy and investments have stimulated funding of at least $3 billion in research related to T1D from third parties, especially government funders. As we move toward curing T1D, we are accelerating the development of therapies that can significantly help people lead fuller, safer lives today and every day.”